Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Pre-treatment	STARTED	Rituximab-Lenalidomide	513
Pre-treatment	STARTED	Investigator Choice	517
Pre-treatment	COMPLETED	Rituximab-Lenalidomide	507
Pre-treatment	COMPLETED	Investigator Choice	503
Pre-treatment	NOT COMPLETED	Rituximab-Lenalidomide	6
Pre-treatment	NOT COMPLETED	Investigator Choice	14
Treatment	STARTED	Rituximab-Lenalidomide	507
Treatment	STARTED	Investigator Choice	503
Treatment	COMPLETED	Rituximab-Lenalidomide	350
Treatment	COMPLETED	Investigator Choice	357
Treatment	NOT COMPLETED	Rituximab-Lenalidomide	157
Treatment	NOT COMPLETED	Investigator Choice	146

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01476787/flow